메뉴 건너뛰기




Volumn 11, Issue , 2011, Pages

Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; SUNITINIB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE;

EID: 79953075835     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-105     Document Type: Article
Times cited : (33)

References (11)
  • 1
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alpha in metastatic renal cell carcinoma
    • 10.1056/NEJMoa065044, 17215529
    • Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alpha in metastatic renal cell carcinoma. New Engl J Med 2007, 356(2):115-124. 10.1056/NEJMoa065044, 17215529.
    • (2007) New Engl J Med , vol.356 , Issue.2 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 2
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell-renal-cell carcinoma
    • 10.1056/NEJMoa060655, 17215530
    • Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell-renal-cell carcinoma. N Engl J Med 2007, 356(2):125-134. 10.1056/NEJMoa060655, 17215530.
    • (2007) N Engl J Med , vol.356 , Issue.2 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 3
    • 68949145218 scopus 로고    scopus 로고
    • Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009,
    • (2009) J Clin Oncol
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 4
    • 70249097380 scopus 로고    scopus 로고
    • Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
    • Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncology 2009, 27(20):3312-3318.
    • (2009) J Clin Oncology , vol.27 , Issue.20 , pp. 3312-3318
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 5
    • 0028223112 scopus 로고
    • Generalizing the results of randomized clinical trials
    • 10.1016/0197-2456(94)90024-8, 8149769
    • Bailey K. Generalizing the results of randomized clinical trials. Controlled Clin Trials 1994, 15:15-23. 10.1016/0197-2456(94)90024-8, 8149769.
    • (1994) Controlled Clin Trials , vol.15 , pp. 15-23
    • Bailey, K.1
  • 6
    • 67651201656 scopus 로고    scopus 로고
    • Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
    • Published online
    • Gore M, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. The Lancet 2009, Published online.
    • (2009) The Lancet
    • Gore, M.1    Szczylik, C.2    Porta, C.3
  • 7
    • 79954966059 scopus 로고    scopus 로고
    • The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access program in North America: Safety and efficacy [ASCO abstract 5011 and associated presentation]
    • accessed: Aug 3, 2009
    • Knox JJ, Figlin RA, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access program in North America: Safety and efficacy [ASCO abstract 5011 and associated presentation]. accessed: Aug 3, 2009., http://www.asco.org/ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_session_presentations_view&confID=47&sessionID=139
    • Knox, J.J.1    Figlin, R.A.2    Stadler, W.M.3
  • 8
    • 67650173972 scopus 로고    scopus 로고
    • Hypotheroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy
    • 10.1038/nrclinonc.2009.4, 19333228
    • Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G. Hypotheroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009, 6:219-228. 10.1038/nrclinonc.2009.4, 19333228.
    • (2009) Nat Rev Clin Oncol , vol.6 , pp. 219-228
    • Torino, F.1    Corsello, S.M.2    Longo, R.3    Barnabei, A.4    Gasparini, G.5
  • 10
    • 33646783722 scopus 로고    scopus 로고
    • Common Terminology Criteria for Adverse Events v 3.0 (CTCAE)
    • accessed: Jun 26, 2008, National Cancer Institute
    • National Cancer Institute Common Terminology Criteria for Adverse Events v 3.0 (CTCAE). 2006, accessed: Jun 26, 2008, National Cancer Institute., http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
    • (2006)
  • 11
    • 77149126422 scopus 로고    scopus 로고
    • Safety and Efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
    • 10.1002/cncr.24864, 20082451
    • Stadler WM, Figlin RA, McDermott DF, et al. Safety and Efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010, 116:1272-1280. 10.1002/cncr.24864, 20082451.
    • (2010) Cancer , vol.116 , pp. 1272-1280
    • Stadler, W.M.1    Figlin, R.A.2    McDermott, D.F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.